- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer
- Interventions
- androgen deprivation therapy, laboratory biomarker analysis, quality-of-life assessment, stereotactic body radiation therapy
- Drug · Other · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 901
matching trials from the local directory fallback.
- Conditions
- Castration-Resistant Prostatic Cancer, Hormone-Refractory Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
- Interventions
- Abiraterone Acetate, Enzalutamide, GnRH agonist/antagonist, Prednisone
- Drug · Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2029
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more
- Conditions
- Prostate Cancer
- Interventions
- CART-PSMA-TGFβRDN cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2038
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Stereotactic Ablative Radiotherapy
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2030
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Prostate Cancer
- Interventions
- HEIGHT RT, LEAD RT
- Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 35 Years to 85 Years · Male only
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2031
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Prostate Cancer
- Interventions
- Poly(ADP Ribose) Polymerase 1, [18F]FluorThanatrace
- Drug · Device
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- SUPR-SABR treatment
- Radiation
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Prostate Adenocarcinoma, Prostate Cancer
- Interventions
- Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
- Drug · Diagnostic Test
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
- Interventions
- Leuprolide, Radiation therapy, Relugolix
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Enfortumab vedotin
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Prostate Cancer
- Interventions
- Interviews, Kegel exercises, Pelvic Floor Muscle Exercise Program with biofeedback, Questionnaires
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Brain Cancer, Breast Cancer, GBM, Glioblastoma, Glioblastoma Multiforme, Melanoma Recurrent, Melanoma Stage IV, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Newly Diagnosed Glioblastoma, Prostate Cancer, Prostate Cancer Metastatic, Recurrent Glioblastoma
- Interventions
- Radiation, ST101, Temozolomide
- Radiation · Drug
- Lead sponsor
- Sapience Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Degarelix, Enzalutamide, Goserelin Acetate, Leuprolide Acetate, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Rucaparib camsylate
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 414
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more
- Conditions
- Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Abiraterone Acetate, Apalutamide, Leuprolide Acetate, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- biopsy, dynamic contrast-enhanced MRI (DCE), multi-parametric MRI(MP-MRI)
- Procedure · Device
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 8
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
- Conditions
- Benign Prostatic Hyperplasia, Localized Prostate Cancer
- Interventions
- Robotic Waterjet Treatment
- Device
- Lead sponsor
- PROCEPT BioRobotics
- Industry
- Eligibility
- Up to 80 Years · Male only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- La Mesa, California • Glenview, Illinois • Alexandria, Virginia
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Interventions
- Attention Control, Supervised Home-Based Exercise, Unsupervised Home-Based Exercise
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Interventions
- NUV-1511
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 466 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Detroit, Michigan • Hackensack, New Jersey • New York, New York + 5 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Stage IVB Prostate Cancer AJCC v8
- Interventions
- PSMA Positron Emission Tomography (PET) Scan, Radium-223, Technetium Tc 99M Medronate
- Procedure · Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Abiraterone, Enzalutamide, [Lu-177]-PNT2002
- Drug
- Lead sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Bone Scan, Computed Tomography, Electronic Health Record Review, Gallium Ga 68 Gozetotide, Magnetic Resonance Imaging, Positron Emission Tomography
- Procedure · Other · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- CDX-301, PGV-001, Poly-ICLC
- Biological
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Prostate Cancer
- Interventions
- robotic radical prostatectomy
- Procedure
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,531 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio